(Q37159547)

18 August 2017

1 reference

title

Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma (English)

1 reference

18 August 2017

Stephanie L Wethington

series ordinal

1

1 reference

PubMed ID

18471053

18 August 2017

Jason D Wright

series ordinal

2

1 reference

PubMed ID

18471053

18 August 2017

Thomas J Herzog

series ordinal

3

1 reference

18 August 2017

1 May 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

819-831

1 reference

18 August 2017

5

1 reference

Update on the role of topotecan in the treatment of recurrent ovarian cancer

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Camptothecin and taxol: historic achievements in natural products research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.819

21 January 2018

Identifiers

DOI

10.1586/14737140.8.5.819

1 reference

18 August 2017

1 reference

PubMed ID

18471053